Prof Daniel Catenacci speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about updates from the FIGHT study.
Prof Catenacci explains that the phase II study is of bemarituzumab combined with modified FOLFOX6 in first line FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma, and that they were presenting the results of updated analyses in patient subgroups, additional data on adverse events and the median overall survival.
He reports that this treatment was beneficial across all the subgroups, but that there was more profound benefit in some of the groups. He describes some of the adverse events, and notes that there may be opportunity to mitigate these but more assessment is required.
Prof Catenacci concludes by discussing candidate biomarkers with promising efficacy endpoints, saying there is a promising future of personalised treatments and potential combination therapies for these patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.